Skip to main content
. 2021 Sep;32(9):2352–2361. doi: 10.1681/ASN.2021020167

Figure 4.

Figure 4.

LS mean change in eGFR over the study in those with baseline stage 4 or stages 2/3 CKD. On the basis of the two-slope model. Total slopes (SEM): stage 4 CKD, dapagliflozin −2.15 (0.32), placebo −3.38 (0.31); stage 2/3 CKD, dapagliflozin −2.98 (0.12), placebo −3.87 (0.12) ml/min per 1.73 m2 per year. Chronic slope (SEM): stage 4 CKD, dapagliflozin −1.33 (0.32), placebo −3.68 (0.12); stage 2/3 CKD, dapagliflozin −1.73 (0.12), placebo −3.68 (0.12) ml/min per 1.73 m2 per year. Acute slope (SEM): stage 4 CKD, dapagliflozin −2.10 (0.37), placebo −0.68 (0.35); stage 2/3 CKD, dapagliflozin −3.19 (0.15), placebo −0.64 (0.15) ml/min per 1.73 m2 per two weeks. Stage 4 CKD, eGFR<30 ml/min per 1.73 m2; stages 2/3 CKD, eGFR 30 ml/min per 1.73 m2. Error bars indicate SEM. LS, least squares; SEM, standard error of the mean.